Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3826
loanDepot
LDI
$215M
| $478K | ﹤0.01% |
230,946
+105,175
| +84% | +$292K |
2025 Q2
2 quarters
|
|
3827
Citizens Financial Services
CZFS
$389M
| $478K | ﹤0.01% |
8,375
+1,155
| +16% | +$65.7K |
2023 Q1
11 quarters
|
|
|
GBFH
3828
GBank Financial Holdings
GBFH
$260M
| $475K | ﹤0.01% |
14,029
+1,348
| +11% | +$49.4K |
2025 Q2
2 quarters
|
|
3829
Portillo's
PTLO
$255M
| $475K | ﹤0.01% |
104,651
+20,801
| +25% | +$109K |
2022 Q1
15 quarters
|
|
|
ATAI
3830
DELISTED
AtaiBeckley Inc
ATAI
| $474K | ﹤0.01% |
115,940
+18,402
| +19% | +$86.8K |
2022 Q1
15 quarters
|
|
|
ONIT
3831
Onity Group
ONIT
$228M
| $474K | ﹤0.01% |
10,344
+1,000
| +11% | +$41.1K |
2022 Q1
15 quarters
|
|
3832
Organon & Co
OGN
$3.6B
| $473K | ﹤0.01% |
65,900
-61,550
| -48% | -$486K |
2022 Q1
15 quarters
|
|
3833
SIGA Technologies
SIGA
$243M
| $472K | ﹤0.01% |
77,325
+4,707
| +6% | +$33.5K |
2018 Q1
31 quarters
|
|
3834
Granite Ridge Resources
GRNT
$590M
| $471K | ﹤0.01% |
100,241
-308,667
| -75% | -$1.59M |
2023 Q1
11 quarters
|
|
|
FRMM
3835
Forum Markets
FRMM
$63.8M
| $471K | ﹤0.01% |
96,082
+93,708
| +3,947% | +$1.32M |
2025 Q3
1 quarter
|
|
3836
CALL
Old Dominion Freight Line
ODFL
$37.4B
| $470K | ﹤0.01% |
3,000
| – | – |
2024 Q4
4 quarters
|
|
3837
Vanguard International Dividend Appreciation ETF
VIGI
$8.84B
| $470K | ﹤0.01% |
5,140
-1,270
| -20% | -$115K |
2023 Q4
8 quarters
|
|
3838
Atlanta Braves Holdings Series A
BATRA
$3.7B
| $470K | ﹤0.01% |
11,061
+1,423
| +15% | +$61.2K |
2023 Q4
8 quarters
|
|
3839
First Capital
FCAP
$210M
| $470K | ﹤0.01% |
7,936
+483
| +6% | +$23.9K |
2019 Q2
26 quarters
|
|
3840
CALL
Synopsys
SNPS
$93.9B
| $470K | ﹤0.01% |
1,000
| – | – |
2025 Q2
2 quarters
|
|
3841
OrthoPediatrics
KIDS
$579M
| $469K | ﹤0.01% |
26,405
+2,561
| +11% | +$44.8K |
2017 Q4
32 quarters
|
|
3842
Invesco S&P 500 Low Volatility ETF
SPLV
$7.03B
| $469K | ﹤0.01% |
6,560
-1,070
| -14% | -$76.9K |
2023 Q4
8 quarters
|
|
|
TECX
3843
Tectonic Therapeutic
TECX
$441M
| $468K | ﹤0.01% |
22,443
+4,467
| +25% | +$83K |
2018 Q2
30 quarters
|
|
3844
MasterCraft Boat Holdings
MCFT
$489M
| $468K | ﹤0.01% |
24,725
+1,769
| +8% | +$34.9K |
2015 Q3
41 quarters
|
|
|
VIOT
3845
Viomi Technology
VIOT
$103M
| $467K | ﹤0.01% |
253,980
+70,810
| +39% | +$187K |
2025 Q2
2 quarters
|
|
|
VIA
3846
Via Transportation Inc
VIA
$2.39B
| $467K | ﹤0.01% |
16,099
+4,617
| +40% | +$191K |
2025 Q3
1 quarter
|
|
|
HDSN
3847
Hudson Technologies
HDSN
$220M
| $466K | ﹤0.01% |
67,991
+7,443
| +12% | +$58.7K |
2022 Q2
14 quarters
|
|
3848
MaxCyte
MXCT
$110M
| $465K | ﹤0.01% |
300,280
+8,639
| +3% | +$13.8K |
2021 Q3
17 quarters
|
|
|
MPLT
3849
MapLight Therapeutics
MPLT
$546M
| $464K | ﹤0.01% |
+26,415
| New | +$443K |
2025 Q4
0 quarters
|
|
3850
NRC Health Common Stock
NRC
$450M
| $464K | ﹤0.01% |
24,704
+412
| +2% | +$6.22K |
2016 Q1
39 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.